MedPath

Vortioxetine

Generic Name
Vortioxetine
Brand Names
Brintellix, Trintellix
Drug Type
Small Molecule
Chemical Formula
C18H22N2S
CAS Number
508233-74-7
Unique Ingredient Identifier
3O2K1S3WQV
Background

Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.

Indication

用于治疗重度抑郁症成人患者。

Associated Conditions
Major Depressive Disorder (MDD)

Antidepressant Vortioxetine Shows Promise in Treating Glioblastoma in Preclinical Studies

• Researchers have identified vortioxetine, an FDA-approved antidepressant, as a potential treatment for glioblastoma, an aggressive brain tumor, due to its ability to cross the blood-brain barrier. • Preclinical studies in cell cultures and mice demonstrated that vortioxetine effectively suppressed glioblastoma cell growth, especially when combined with standard treatments like chemotherapy and radiation. • The research team is preparing for clinical trials to evaluate the efficacy of vortioxetine in human glioblastoma patients, with cautious optimism about its potential to improve treatment outcomes. • Experts caution against self-medication with vortioxetine, emphasizing the need for clinical trials to determine appropriate dosages and confirm its effectiveness and safety in humans.
© Copyright 2025. All Rights Reserved by MedPath